89bio, Inc. Deferred Tax Assets, Valuation Allowance
89bio, Inc. had Deferred Tax Assets, Valuation Allowance of $214.59 million as of 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance
us-gaap:DeferredTaxAssetsValuationAllowance · last filed 2025-02-27
- 2024-12-31: Deferred Tax Assets, Valuation Allowance $214.59M.
- 2023-12-31: Deferred Tax Assets, Valuation Allowance $108.23M.
- 2022-12-31: Deferred Tax Assets, Valuation Allowance $75.98M.
- 2021-12-31: Deferred Tax Assets, Valuation Allowance $42.05M.
| Period end | Deferred Tax Assets, Valuation Allowance |
|---|---|
| 2024-12-31 | $214.59M 10-K · filed 2025-02-27 |
| 2023-12-31 | $108.23M 10-K · filed 2025-02-27 |
| 2022-12-31 | $75.98M 10-K · filed 2024-03-01 |
| 2021-12-31 | $42.05M 10-K · filed 2023-03-15 |
| 2020-12-31 | $21.94M 10-K · filed 2022-03-24 |
| 2019-12-31 | $10.02M 10-K · filed 2021-03-25 |
| 2018-12-31 | $3.50M 10-K · filed 2020-03-18 |